Fig. 1From: Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CReal-life prevalence of NS5A resistance-associated variants (RAVs) in patients with chronic hepatitis C genotype IbBack to article page